Close

Axovant Sciences (AXON) trading paused for volatility

Go back to Axovant Sciences (AXON) trading paused for volatility

Baird Defends Axovant Sciences (AXON) After Lundbeck; No Change to Outlook

September 22, 2016 1:35 PM EDT

Baird analyst Brian Skorney came out to defend Axovant Sciences (NYSE: AXON), which is getting slammed on rival Lundbeck top-line results.

Skorney commented, "Lundbeck reported failure of Phase 3 STARSHINE trial of idolapirdine, a 5-HT6 antagonist, sending shockwaves through Axovant's stock. However, we... More

Axovant Sciences (AXON) Shares Resume Trading, Look to Bounce Higher

September 22, 2016 12:18 PM EDT

Axovant Sciences (NYSE: AXON) resumes trading. Shares are down over 24 percent, but bouncing a bit higher.

... More